Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F22%3A43923495" target="_blank" >RIV/00064173:_____/22:43923495 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/22:43923495
Result on the web
<a href="https://doi.org/10.1038/s41408-022-00668-8" target="_blank" >https://doi.org/10.1038/s41408-022-00668-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41408-022-00668-8" target="_blank" >10.1038/s41408-022-00668-8</a>
Alternative languages
Result language
angličtina
Original language name
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Original language description
Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO) + AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of >=10, 5, or 7 points for GHS/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN + AZA vs PBO + AZA patients had longer TTD in GHS/QoL (P = 0.066) and fatigue (P = 0.189), and significantly longer TTD in PF (P = 0.028) and HS-VAS (P < 0.001). VEN + LDAC vs PBO + LDAC patients had significantly longer TTD in GHS/QoL (P = 0.011), PF (P = 0.020), and fatigue (P = 0.004), and a trend in HS-VAS (P = 0.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN + AZA, AZA + PBO, VEN + LDAC, or LDAC + PBO, respectively, saw improvements >MCT in GHS/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Cancer Journal
ISSN
2044-5385
e-ISSN
2044-5385
Volume of the periodical
12
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
71
UT code for WoS article
000784973500004
EID of the result in the Scopus database
2-s2.0-85128459880